NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DA-22-058 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-100 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-133 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-106 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-194 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to use the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of heart, lung, blood, and sleep (HLBS) disorders. The overall goal is to transition the program from genetic Map to Mechanism (M2) and to fill knowledge gaps that have not been sufficiently covered by existing TOPMed datasets. No funding will be provided under this FOA. The omics and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC).
Notice NOT-DK-22-022 from the NIH Guide for Grants and Contracts
Notice NOT-AG-22-022 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-087 from the NIH Guide for Grants and Contracts
Notice NOT-ES-22-006 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-136 from the NIH Guide for Grants and Contracts
Notice NOT-HG-22-020 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-185 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B, Hepatitis C and Tuberculosis).
Notice NOT-OD-22-134 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-22-023 from the NIH Guide for Grants and Contracts. This RFA is soliciting applications to support data science and innovation research projects at African institutions, as part of a broader Common Fund effort. Applications to this RFA will require unique and diverse reviewer expertise, including data science, engineering, biomedical science, and global health (with perspectives from Africa). Additionally, this RFA has unique objectives (related to the RFA and the broader program) and review criteria.
Funding Opportunity RFA-RM-22-022 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that complement and/or enhance the training of a diverse workforce to meet the biomedical, behavioral and clinical research needs of the Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) program. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. Applications are encouraged that propose innovative, state-of-the-art, hands-on programs that advance the goal of DS-I Africa. The courses should focus on activities that target educational needs or gaps in the DS-I Africa consortium, and thus applicants must have support from current DS-I Africa awardees. Applications must be submitted from African academic or other non-profit organizations.
Funding Opportunity RFA-HD-23-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will utilize 3D bioprinting technologies to develop tissue constructs for long-term use that will adapt to the needs of growing children, and for obstetric and gynecological conditions. The overall goal of this initiative is to promote the clinical translation of bioprinted tissue constructs by helping to identify and working to overcome current barriers to preclinical product development, validation and verification. This will ultimately enable evidence generation for regulatory approval and human testing of mature bioprinted tissue constructs addressing the unmet needs of NICHD mission-relevant gynecologic, obstetric and pediatric diseases and disorders. Of note, this FOA is not intended for early stage, hypothesis validation of new bioprinted tissue constructs not yet mature for pursuing clinical translation or to support large scale clinical trials using bioprinted tissue constructs.
Notice NOT-DE-22-011 from the NIH Guide for Grants and Contracts
Notice NOT-DE-22-010 from the NIH Guide for Grants and Contracts
Notice NOT-DE-22-009 from the NIH Guide for Grants and Contracts
Notice NOT-HL-22-024 from the NIH Guide for Grants and Contracts